Financial reports
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
14 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
10 Aug 21
Current reports
8-K
Completion of Acquisition or Disposition of Assets
11 Aug 23
8-K
Lilly to Acquire Sigilon Therapeutics
29 Jun 23
8-K
Termination of a Material Definitive Agreement
22 May 23
8-K
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
9 May 23
8-K
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
14 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Other Events
28 Feb 23
8-K
Departure of Directors or Certain Officers
13 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Dec 22
8-K
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
10 Nov 22
Registration and prospectus
15-12G
Securities registration termination
21 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
POS AM
Prospectus update (post-effective amendment)
11 Aug 23
25-NSE
Exchange delisting
11 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
10 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
10 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
1 Aug 23
Proxies
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
PRE 14A
Preliminary proxy
23 Mar 23
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
Other
EFFECT
Notice of effectiveness
16 Aug 23
EFFECT
Notice of effectiveness
25 Apr 22
CORRESP
Correspondence with SEC
20 Apr 22
UPLOAD
Letter from SEC
19 Apr 22
EFFECT
Notice of effectiveness
4 Dec 20
UPLOAD
Letter from SEC
4 Dec 20
CERT
Certification of approval for exchange listing
3 Dec 20
CORRESP
Correspondence with SEC
1 Dec 20
CORRESP
Correspondence with SEC
1 Dec 20
CORRESP
Correspondence with SEC
24 Nov 20
Ownership
SC 13G/A
Flagship Ventures Fund V, L.P.
14 Feb 24
4
NOUBAR AFEYAN
15 Aug 23
SC 13D/A
ELI LILLY & Co
14 Aug 23
4
Change in insider ownership
14 Aug 23
4
Douglas G. Cole
11 Aug 23
4
Stephen N. Oesterle
11 Aug 23
4
Eric D. Shaff
11 Aug 23
4
ROBERT R RUFFOLO
11 Aug 23
4
John Cox
11 Aug 23
4
Matthew Paul Kowalsky
11 Aug 23